The Chemical and Biological Route from Podophyllotoxin Glucoside to Etoposide: Ninth Cain Memorial Award Lecture

Cancer Research

Volumn 51, Issue 1, 1991, Pages 5-15

  Stähelin, Hartmann F ^a   von Wartburg, Albert ^a  

^a Preclinical Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; ETOPOSIDE; PODOPHYLLOTOXIN; PODOPHYLLOTOXIN GLUCOSIDE; TENIPOSIDE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL;

ALDEHYDES; ANTINEOPLASTIC AGENTS; CELL DIVISION; CYCLOSPORINS; ETOPOSIDE; GLUCOSIDES; GROWTH INHIBITORS; HISTORY OF MEDICINE, 19TH CENT.; HISTORY OF MEDICINE, 20TH CENT.; PLANTS, MEDICINAL; PLANTS, TOXIC; PODOPHYLLOTOXIN; PODOPHYLLUM; STRUCTURE-ACTIVITY RELATIONSHIP; TENIPOSIDE;

EID: 0026011121     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Kaplan, I. W. Condylomata acuminata. New Orleans Med. Surg. J., 94: 388–390, 1942.
2. Podwyssotzki, V. Pharmakologische Studien über Podophyllum peltatum. Arch. Exp. Pathol. Pharmakol., 13: 29–52, 1880.
3. Hartwell, J. L., and Schrecker, A. W. Components of podophyllin. V. The constitution of podophyllotoxin. J. Am. Chem. Soc., 73: 2909–2916, 1951.
4. Kelly, M. G., and Hartwell, J. L. The biological effects and the chemical composition of podophyllin. A review. J. Natl. Cancer Inst., 14: 967–1010, 1954.
5. Hartwell, J. L., and Schrecker, A. W. The chemistry of Podophyllum. Prog. Chem. Org. Nat. Prod., 15: 83–166, 1958.
6. Stähelin, H., and von Wartburg, A. From podophyllotoxin glucoside to etoposide. Prog. Drug Res., 33: 169–266, 1989.
7. Stoll, A., Renz, J., and von Wartburg, A. The isolation of podophyllotoxin glucosid. J. Am. Chem. Soc., 76: 3103–3104, 1954.
8. Stoll, A., Renz, J., and von Wartburg, A. Die Isolierung von Podophyllotoxin-glucoside aus dem indischen Podophyllum emodi Wall. Helv. Chim. Acta, 37: 1747–1762, 1954.
9. Stoll, A., von Wartburg, A., Angliker, E., and Renz, J. The isolation of 4’-demethylpodophyllotoxin glucoside from rhizomes of Podophyllum emodi Wall. J. Am. Chem. Soc., 76: 5004, 1954.
10. Stoll, A., von Wartburg, A., Angliker, E., and Renz, J. Glucosides from the rhizomes of Podophyllum peltatum Linn. J. Am. Chem. Soc., 76: 6413–6414, 1954.
11. Stoll, A., von Wartburg, A., and Renz, J. The isolation of α-peltatin glucoside from the rhizomes of Podophyllum peltatum L. J. Am. Chem. Soc., 77: 1709–1710, 1955.
12. von Wartburg, A., Angliker, E., and Renz, J. Lignanglucoside aus Podophyllum peltatum L. Helv. Chim. Acta, 40: 1331–1357, 1957.
13. Stähelin, H. A simple quantitative test for cytostatic agents using non-adhering cells in vitro. Med. Exp., 7: 92–102, 1962.
14. Stähelin, H., and Cerletti, A. Experimentelle Ergebnisse mit den Podophyllum-Cytostatica SP-I und SP-G. Schweiz. Med. Wochenschr., 94: 1490–1502, 1964.
15. Cerletti, A., Emmenegger, H., and Stähelin, H. Recherches sur les propriétés antimitotiques de substances dérivées de la podophyllotoxine. Actualités Pharmacol. (Paris), 12: 103–128, 1959.
16. Kuhn, M., Keller-Juslèn, C., and von Wartburg, A. Partialsynthese von 4’-Demethylepipodophyllotoxin. Helv. Chim. Acta, 52: 944–947, 1969.
17. Kuhn, M., and von Wartburg, A. Ueber ein neues Glykosidierungsverfahren. II. Glykoside des 4’-Demethylepipodophyllotoxins. Helv. Chim. Acta, 52: 948–955, 1969.
18. King, L. S., and Sullivan, M. The similarity of the effect of podophyllin and colchicine and their use in the treatment of condylomata acuminata. Science (Washington DC), 104: 244–245, 1946.
19. 14C-Diazomethan. Helv. Chim. Acta, 39: 993–999, 1956.
20. Emmenegger, H., Stähelin, H., Rutschmann, J., Renz, J., and von Wartburg A. Zur Chemie und Pharmakologie der Podophyllum-Glukoside und ihrer Derivate. Drug Res., 11: 327–333, 459–469, 1961.
21. Weder, A. Klinische Demonstration. Schweiz. Med. Wochenschr., 88: 625, 1958.
22. Lazary, S., and Stähelin, H. Immunosuppressive Wirkung von Podophyllumstoffen und andern Cytostatica. In: K. H. Spitzy (ed.,), Fifth International Congress of Chemotherapy, Vol. 3, p. 317. Vienna: Verlag Wiener Mediz. Akademie, 1967; and Stähelin, H., unpublished results, 1964.
23. Rutschmann, J., and Renz, J. Ueber Säurehydrazide aus der Podophyllotoxin-Reihe. Helv. Chim. Acta, 42: 890–907, 1959.
24. Kuhn, M., and von Wartburg, A. Synthese des Neopodophyllotoxins und der Podophyllinsäure. Experientia (Basel), 19: 391–393, 1963.
25. Renz, J., Kuhn, M., and von Wartburg, A. Umesterungsreaktionen an Podophyllum-Lignanen. Justus Liebigs Ann. Chem., 681: 207–224, 1965.
26. Kuhn, M., and von Wartburg, A. Podophyllum Lignane: Struktur und Absolutkonfiguration von Podorhizol-β-D-glucosid (= Lignan F). Helv. Chim. Acta, 50: 1546–1565, 1967.
27. von Wartburg, A., Kuhn, M., and Lichti, H. Podophyllum Lignane: 4’-Demethyldesoxypodophyllotoxin-β-D-glucosid, ein neues Glykosid aus Podophyllum emodi Wall. und P. peltatum L. Helv. Chim. Acta, 47: 1203–1210, 1964.
28. Kuhn, M., and von Wartburg, A. Desoxypodophyllinsaure-1-β-D-glucopyra-nosylester, ein neues Lignanderivat aus Podophyllum peltatum L. und P. emodi Wall. Helv. Chim. Acta, 46: 2127–2139, 1963.
29. Goldin, A., Serpick, A. A., and Mantel, N. Experimental screening procedures and clinical predictability value. Cancer Chemother. Rep., 50: 172–218, 1966.
30. Kuhn, M., Keller-Juslén, C., and von Wartburg, A. Partialsynthese von 4’-Demethylepipodophyllotoxin. Helv. Chim. Acta, 52: 944–947, 1969.
31. Kuhn, M., and von Wartburg, A. Abspaltung von Acyl-Schutz-gruppen bei alkaliempfindlichen Glucosiden. Synthese von Podophyllotoxin-β-D-glu-cosid. Helv. Chim. Acta. 51: 163–168, 1968.
32. Kuhn, M., and von Wartburg, A. Ueber ein neues Glykosidierungsverfahren. Synthese von Epipodophyllotoxin-β-D-glucopyranosid. Helv. Chim. Acta. 51: 1631–1641, 1968.
33. Chen, Y., Wang, Y., Li, J., Tian, X., Jia, Z., and Zhang, P. Anticancer drugs II. Synthesis and biological evaluation of spin labeled derivatives of podophyllotoxin. Life Sci., 45: 2569–2575, 1989.
34. Lee, K., Imakura, Y., Haruna, M., Beers, S. A., Thurston, L. S., Dai, H., and Chen, C. Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4’-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J. Natural Prod., 52: 606–613, 1989.
35. Keller-Juslén, C., Kuhn, M., von Wartburg, A., and Stähelin, H. Synthesis and antimitotic activity of glycosidic derivatives related to podophyllotoxin. J. Med. Chem., 14: 936–940, 1971.
36. Kreis, W., and Soricelli, A. Comparison of a water-soluble and a water-insoluble podophyllotoxin derivative in murine neoplasms. J. Cancer Res. Clin. Oncol., 95: 233–237, 1979.
37. Stähelin, H. VM 26, a new podophyllotoxin glucoside derivative with anti-L-1210 activity. Proc. Am. Assoc. Cancer Res., 10: 86, 1969.
38. Stähelin, H. 4’-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. Eur. J. Cancer, 6: 303–311, 1970.
39. Muggia, F. M. Phase I study of 4’ demethyl-epipodophyllotoxin-β-D-theny-lidene glucoside (PTG, NSC 122819). Proc. Am. Assoc. Cancer Res. 11: 58, 1970.
40. Trempe, G., Sykes, M., Young, C., and Krakoff, I. Phase 1 trial of the podophyllotoxin derivative VM-26. Proc. Am. Assoc. Cancer Res., 11: 79, 1970.
41. Stähelin, H. Activity of a new glycosidic lignan derivative (VP 16–213) related to podophyllotoxin in experimental tumors. Eur. J. Cancer, 9: 215–221, 1973.
42. Stähelin, H. Reversibility of the cytostatic effect of the podophyllotoxin derivative VP 16–213. In: G. K. Daikos (ed.), Progress in Chemotherapy, Vol. 3, pp. 819–823. Athens: Hellenic Society of Chemotherapy, 1974.
43. Stähelin, H. Cycle dependency and reversibility of the effect of some cytostatic drugs; their significance for dosage schedules. In: L. M. van Putten (ed.), Workshop on Clinical Usefulness of Cell Kinetic Information for Tumour Chemotherapy, pp. 21–24. Rijswijk, Netherlands: REP-TNO, 1974.
44. Stähelin, H. Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16–213), due to a local effect. Eur. J. Cancer, 12: 925–931, 1976.
45. Stähelin, H. Ciclosporin: historical background. Prog. Allergy, 38: 19–27, 1986.
46. Rozencweig, M., Von Hoff, D. D., Henney, J. E., and Muggia, F. M. VM 26 and VP 16–213. A comparative analysis. Cancer (Phila.), 40: 334–342 (1977).
47. O’Dwyer, P. J., Alonso, M. T., Leyland-Jones, B., and Marsoni, S. Teniposide: a review of 12 years of experience. Cancer Treat. Rep., 68: 1455–1466, 1984.
48. O’Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S., and Wittes, R. E. Etoposide (VP 16–213). Current status of an active anticancer drug. N. Engl. J. Med., 312: 692–700, 1985.
49. Seeber, S., Nagel, G. A., Acherrath, W., Schmidt, C. G., and Raettig, R. (eds.), Etoposid, derzeitiger Stand und neue Entwicklungen in der Chemotherapie maligner Neoplasien. (Aktuelle Onkologie, vol. 4). Munich, W. Germany: Zuckschwerdt Verlag, 1981.
50. Schwarzmeier, J., Deutsch, E., and Karrer, K. (eds.). Etoposid (VP 16–213) in der Therapie maligner Erkrankungen. New York: Springer-Verlag, 1984.
51. Issell, B. F., Muggia, F. M., and Carter, S. K. (eds.). Etoposide (VP-16), Current Status and New Developments. Orlando, FL; Academic Press, 1984.
52. Dombernowsky, P., and Hansen, H. H. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects. Eur. J. Haematol., 42 (Suppl. 48): 49–57, 1989.
53. Henwood, J. M., and Brogden, R. N. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy in cancer. Drugs, 39: 438–490, 1990.
54. Gralla, R. J., and Einhorn, L. H. (eds.). Treatment and Prevention of Small Cell Lung Cancer and Non-Small Cell Lung Cancer. International Congress and Symposium Series No. 150. London: Royal Society of Medical Services, 1989.
55. Hansen, H. H. (ed.). Vepesid and Vumon. A status report. Brochure on Meeting Charlottenlund, Denmark, Sept. 1988.
56. Stadtmauer, E. A., Cassileth, P. A., and Gale, R. P. Etoposide in leukemia, lymphoma and bone marrow transplantation. Leuk. Res., 13: 639–650, 1989.
57. Bostrom, B., Weisdorf, D. J., Kim, T., Kersey, J. H., and Ramsay, N. K. C. Bone marrow transplantation for advanced leukemia: a pilot study of high energy total body irradiation, cyclophosphamide and continuous infusion of etoposide. Bone Marrow Transplant., 5: 83–89, 1990.
58. Stähelin, H. Chemie und Wirkungsmechanismus von Podophyllinderivaten. Planta Med., 22: 336–347, 1972.
59. 3H-leucine by P-815 mastocytoma cells in vitro. In: Tenth International Cancer Congress, Preferred Papers, p. 398, Houston, 1970.
60. Batz, K., Kalberer, F., and Stähelin, H. Aufnahme von Thymidin durch Mastocytomzellen in vitro unter der Einwirkung von Podophyllumstoffen. Experientia (Basel), 20: 524–525, 1964.
61. Grieder, A., Maurer, R., and Stähelin, H. Effect of an epipodophyllotoxin derivative (VP 16–213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Res., 34: 1788–1793, 1974.
62. Grieder, A., Maurer, R., and Stähelin, H. Comparative study of early effects of epidophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer Res., 37: 2998–3005, 1977.
63. Loike, J. D., Horwitz, S. B., and Grollman, A. P. Effects of VP 16–213 on HeLa cells. Pharmacologist, 16: 209, 1974.
64. Loike, J. D., and Horwitz, S. B. Effect of VP-16–213 on the intracellular degradation of DNA in HeLa cells. Biochemistry, 15: 5443–5448, 1976.
65. Loike, J. D., and Horwitz, S. B. Effects of podophyllotoxin and VP-16–213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry, 15: 5435–5443, 1976.
66. Long, B. H., and Minocha, A. Inhibition of topoisomerase II by VP-16–213 (etoposide), VM-26 (teniposide), and structural congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc. Am. Assoc. Cancer Res., 24: 321, 1983.
67. van Maanen, J. M. S., Retel, J., de Vries, J., and Pinedo, H. M. Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer Inst., 80: 1526–1533, 1988.
68. Saulnier, M. G., Vyas, D. M., Langley, D. R., Doyle, T. W., Rose, W. C., Crosswell, A. R., and Long, B. H. E-Ring desoxyanalogues of etoposide. J. Med. Chem., 32: 1418–1420, 1989.
69. D’Arpa, P., and Liu, L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989: 163–177, 1989.
70. To, R. Q., and Kmiec, E. B. Assembly of transcriptionally active chromatin in vitro: a possible role for topoisomerase II. Cell Growth Differentiation, 1: 39–45, 1990.
71. Davies, S. M., Davies, S. L., Hall, A. G., and Hickson, I. D. Isolation and partial characterisation of a mammalian cell mutant hypersensitive to topoisomerase II inhibitors and X-rays. Mutat. Res., 235: 111–118, 1990.
72. Lock, R. B., Latham, M. D., and Ross, W. E. Modulation of etoposide or radiation induced G2 arrest and cytotoxicity by caffeine or cycloheximide: involvement of cdc2 kinase. Proc. Am. Assoc. Cancer Res., 31: 395, 1990.
73. Danks, M. K., Schmidt, C. A., Cirtain, M. C., Suttle, D. P., and Beck, W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry, 27: 8861–8869, 1988.
74. Ritke, M. K., and Yalowich, J. C. DNA topoisomerase II expression in human leukemia cells with acquired resistance to etoposide. Proc. Am. Assoc. Cancer Res., 37: 438, 1990.
75. Osieka, R., Seeber, S., Pannenbäcker, R., Soil, D., Glatte, P., and Schmidt, C. G. Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother. Pharmacol., 18: 198–202, 1986.
76. Gaveriaux, C., Boesch, D., Boelsterli, J. J., Bollinger, P., Eberle, M. K., Hiestand, P., Payne, T., Traber, R., Wenger, R., and Loor, F. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Br. J. Cancer, 60: 867–871, 1989.
77. Kelleher, J. K. Correlation of tubulin-binding and antitumor activities of podophyllotoxin analogs. Cancer Treat. Rep., 62: 1443–1447, 1978.
78. Loike, J. D., Brewer, C. F., Sternlich, H., Gensler, W. J., and Horwitz, S. B. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res., 38: 2688–2693, 1978.
79. Long, B. H., Musial, S. T., and Brattain, M. G. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP 16–213 and VM26: a quantitative structure-activity relationship. Biochemistry, 23: 1183–1188, 1984.
80. Borel, J. F., Ruegger, A., and Stähelin, H. Cyclosporin A: a new antilymphocytic agent. Experientia (Basel), 32: 777, 1976.
81. Borel, J. F., Feurer, C., Gubler, H. U., and Stähelin, H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 6: 468–475, 1976.
82. Ruegger, A., Kuhn, M., Lichti, H. Loosli, H. R., Huguenin, R., Quiquerez, C., and von Wartburg, A. Cyclosporin A, ein immunsuppressiv wirksamer Peptidmetabolit aus Trichoderma polysporum (Link ex Pers.) Rifai. Helv. Chim. Acta. 59: 1075–1092, 1976.
83. Von Wartburg, A., and Traber, R. Cyclosporins, fungal metabolites with immunosuppressive activities. Prog. Med. Chem., 25: 1–33, 1988.
84. Stähelin, H. Internal Report on VP 16–213, September 14, 1967.
85. Stähelin, H., Screening Report on Purified Extract (code 24–556) of Tolypo-cladium inflatum, January 31, 1972.
86. Slater, L. M., Wetzel, M., Cho, J., and Sweet, P. Cyclosporin A (CsA) enhancement of VP-16 and production of immunity to L1210 leukemia. Proc. Am. Assoc. Cancer Res., 31: 359, 1990.